Action Overview

Mast cells and basophils have long been recognized for their detrimental role in the elicitation of allergic diseases. In recent years, scientific results revealed both cell types as versatile effector cells that exhibit far more complex functions beyond their role in allergy. Mast cells and basophils have been shown to be critically involved in various innate and adaptive immune responses and, thereby, providing beneficial host protecting immunity. In contrast, they also contribute to the development and maintenance of several chronic inflammatory diseases which, even at the present time, lack sufficient treatment options. The diversity of important mast cell and basophil functions places these cell types into promising therapeutic targets. The Action will create a network of European experts to foster a multidisciplinary approach for the identification, characterisation, and development of such targets and their translation into novel therapeutic strategies.

Domain: Biomedicine and Molecular Biosciences

undefinedParticipating Countries

undefinedManagement Committee

Action details

Draft MoU : oc-2010-1-7310
CSO Approval date : 02/12/2010
Entry into force : 21/01/2011
End of Action : 15/03/2015

Last updated:


News & Events

EMBRN volume on mast cells and basophils and their functions is now in press in Immunological Reviews

Immunological Reviews just published a series of reports on mast cells, basophils and their role in health and disease (Immunological Reviews 2018; Vol 82, page 1-277).

Original and review papers on mast cells / basophils wanted!

Our colleagues Thomas Marichal, Nicolas Gaudenzio, Laurent Reber, and Philipp Starkl are putting together, as guest editors, a Special Issue on the regulation of type 2 immunity by mast cells and...

9th EMBRN International Mast Cell and Basophil Meeting in Uppsala, June 17th to 19th, 2019

We are pleased to let you know that the 9th European Mast Cell and Basophil Research Network (EMBRN) meeting is scheduled to be in Uppsala, Sweden from Monday, June 17th to 19th, 2019. Stay tuned for...


Report Final Conference of COST Action BM1007 (2011-2015)

Mast Cells and Basophils – Targets for Innovative Therapies

Final Report – COST ACTION BM1007 2nd Training School

Jerusalem, Israel, January 20-21, 2014

School of Pharmacy hosts International Training School funded by COST Action BM1007

The School of Pharmacy, University of Nottingham recently hosted an International Training School funded by the COST Action Biomedicine and Molecular Biosciences BM1007 "Mast Cells and Basophils -...

Our Partners